Loading...

John Ward

TitleEmeritus Professor
InstitutionUniversity of California San Diego
DepartmentRadiology
Address9500 Gilman Drive #0610
La Jolla CA 92093
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Reichard CA, Gregg JR, Achim MF, Aparicio AM, Pettaway CA, Pisters LL, Ward J, Davis JW, Chapin BF. Radical Prostatectomy in Metastatic Castration-resistant Prostate Cancer: Feasibility, Safety, and Quality of Life Outcomes. Eur Urol. 2018 Apr 12. PMID: 29656854.
      View in: PubMed
    2. Blanchard P, Davis JW, Frank SJ, Kim J, Pettaway CA, Pugh TJ, Pisters LL, Ward J, Choi S, Chapin BF, Hoffman K, Navai N, Achim M, McGuire SE, Matin SF, Nguyen Q, Mahmood U, Graber WJ, Chen HC, Wang X, Kuban DA. Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort. BJU Int. 2018 Apr; 121(4):540-548. PMID: 28941030.
      View in: PubMed
    3. Li R, Petros FG, Davis CJ, Ward J. Characterization of Glomus Tumors of the Kidney. Clin Genitourin Cancer. 2017 Sep 07. PMID: 28967505.
      View in: PubMed
    4. Basourakos SP, Davis JW, Chapin BF, Ward J, Pettaway CA, Pisters LL, Navai N, Achim MF, Wang X, Chen HC, Choi S, Kuban D, Troncoso P, Hanash S, Thompson TC, Kim J. Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer. BJU Int. 2018 01; 121(1):69-76. PMID: 28710901.
      View in: PubMed
    5. Metcalfe MJ, Troncoso P, Guo CC, Chen HC, Bozkurt Y, Ward J, Pisters LL. Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes. Can Urol Assoc J. 2017 Jul; 11(7):E277-E284. PMID: 28761588.
      View in: PubMed
    6. Gao J, Ward J, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis CJ, Wistuba II, Sepulveda MA, Sun J, Wargo J, Blando J, Sharma P. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med. 2017 May; 23(5):551-555. PMID: 28346412.
      View in: PubMed
    7. Crouzet S, Blana A, Murat FJ, Pasticier G, Brown SCW, Conti GN, Ganzer R, Chapet O, Gelet A, Chaussy CG, Robertson CN, Thuroff S, Ward J. Salvage high-intensity focused ultrasound (HIFU) for locally recurrent prostate cancer after failed radiation therapy: Multi-institutional analysis of 418 patients. BJU Int. 2017 06; 119(6):896-904. PMID: 28063191.
      View in: PubMed
    8. Bilen MA, Hess KR, Campbell MT, Wang J, Broaddus RR, Karam JA, Ward J, Wood CG, Choi SL, Rao P, Zhang M, Naing A, General R, Cauley DH, Lin SH, Logothetis CJ, Pisters LL, Tu SM. Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. Oncotarget. 2016 Dec 27; 7(52):86280-86289. PMID: 27861143.
      View in: PubMed
    9. Kenney PA, Nawaf CB, Mustafa M, Wen S, Wszolek MF, Pettaway CA, Ward J, Davis JW, Pisters LL. Robotic-assisted laparoscopic versus open salvage radical prostatectomy following radiotherapy. Can J Urol. 2016 Jun; 23(3):8271-7. PMID: 27347619.
      View in: PubMed
    10. Pearce SM, Golan S, Gorin MA, Luckenbaugh AN, Williams SB, Ward J, Montgomery JS, Hafez KS, Weizer AZ, Pierorazio PM, Allaf ME, Eggener SE. Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer. Eur Urol. 2017 03; 71(3):476-482. PMID: 27234998.
      View in: PubMed
    11. Kim J, Davis JW, Klein EA, Magi-Galluzzi C, Lotan Y, Ward J, Pisters LL, Basler JW, Pettaway CA, Stephenson A, Li Ning Tapia EM, Efstathiou E, Wang X, Do KA, Lee JJ, Gorlov IP, Vornik LA, Hoque AM, Prokhorova IN, Parnes HL, Lippman SM, Thompson IM, Brown PH, Logothetis CJ, Troncoso P. Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. EBioMedicine. 2016 May; 7:85-93. PMID: 27322462; PMCID: PMC4909608.
    12. Tu SM, Bilen MA, Hess KR, Broaddus RR, Kopetz S, Wei C, Pagliaro LC, Karam JA, Ward J, Wood CG, Rao P, Tu ZH, General R, Chen AH, Nieto YL, Yeung SC, Lin SH, Logothetis CJ, Pisters LL. Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. Cancer. 2016 06 15; 122(12):1836-43. PMID: 27018785.
      View in: PubMed
    13. Williams SB, Ward J. Re: Jan P. Radtke, Constantin Schwab, Maya B. Wolf, et al. Multiparametric Magnetic Resonance Imaging (MRI) and MRI-Transrectal Ultrasound Fusion Biopsy for Index Tumor Detection: Correlation with Radical Prostatectomy Specimen. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.12.052. Eur Urol. 2016 09; 70(3):e77-8. PMID: 26988610.
      View in: PubMed
    14. Mustafa M, Delacroix S, Ward J, Pisters L. The feasibility and safety of repeat cryosurgical ablation of localized prostate cancer. World J Surg Oncol. 2015 Dec 21; 13:340. PMID: 26691335; PMCID: PMC4687344.
    15. Ward J, Eggener SE. Active surveillance monitoring: the role of novel biomarkers and imaging. Asian J Androl. 2015 Nov-Dec; 17(6):882-4; discussion 883. PMID: 26112488; PMCID: PMC4814962.
    16. Williams SB, Davis JW, Wang X, Achim MF, Zurita-Saavedra A, Matin SF, Pisters LL, Ward J, Pettaway CA, Chapin BF. Neoadjuvant Systemic Therapy Before Radical Prostatectomy in High-Risk Prostate Cancer Does Not Increase Surgical Morbidity: Contemporary Results Using the Clavien System. Clin Genitourin Cancer. 2016 Apr; 14(2):130-8. PMID: 26558524.
      View in: PubMed
    17. van den Bos W, Muller BG, de Bruin DM, de Castro Abreu AL, Chaussy C, Coleman JA, Finelli A, Gill IS, Gross ME, Jenniskens SF, Kahmann F, Laguna-Pes MP, Rastinehad AR, Simmons LA, Sulser T, Villers A, Ward J, de la Rosette JJ. Salvage ablative therapy in prostate cancer: international multidisciplinary consensus on trial design. Urol Oncol. 2015 Nov; 33(11):495.e1-7. PMID: 26231310.
      View in: PubMed
    18. Davis JW, Ward J, Pettaway CA, Wang X, Kuban D, Frank SJ, Lee AK, Pisters LL, Matin SF, Shah JB, Karam JA, Chapin BF, Papadopoulos JN, Achim M, Hoffman KE, Pugh TJ, Choi S, Troncoso P, Logothetis CJ, Kim J. Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int. 2016 07; 118(1):68-76. PMID: 26059275.
      View in: PubMed
    19. Parker PA, Davis JW, Latini DM, Baum G, Wang X, Ward J, Kuban D, Frank SJ, Lee AK, Logothetis CJ, Kim J. Relationship between illness uncertainty, anxiety, fear of progression and quality of life in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int. 2016 Mar; 117(3):469-77. PMID: 25714186; PMCID: PMC4547910 [Available on 03/01/17].
    20. Subbiah V, Meric-Bernstam F, Mills GB, Shaw KR, Bailey AM, Rao P, Ward J, Pagliaro LC. Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRß/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial. J Hematol Oncol. 2014 Aug 01; 7:52. PMID: 25085632; PMCID: PMC4237879.
    21. Madsen LT, Kuban DA, Choi S, Davis JW, Kim J, Lee AK, Domain D, Levy L, Pisters LL, Pettaway CA, Ward J, Logothetis C, Hoffman KE. Impact of a clinical trial initiative on clinical trial enrollment in a multidisciplinary prostate cancer clinic. J Natl Compr Canc Netw. 2014 Jul; 12(7):993-8. PMID: 24994920; PMCID: PMC4413899.
    22. Valerio M, Emberton M, Barret E, Eberli D, Eggener SE, Ehdaie B, Jichlinski P, Ward J, Ahmed HU. Health technology assessment in evolution - focal therapy in localised prostate cancer. Expert Rev Anticancer Ther. 2014 Nov; 14(11):1359-67. PMID: 24965212.
      View in: PubMed
    23. Reis LO, Billis A, Zequi SC, Tobias-Machado M, Viana P, Cerqueira M, Ward J. Supporting prostate cancer focal therapy: a multidisciplinary International Consensus of Experts ("ICE"). Aging Male. 2014 Jun; 17(2):66-71. PMID: 24597940.
      View in: PubMed
    24. Ward J, DiBlasio CJ, Williams C, Given R, Jones JS. Cryoablation for locally advanced clinical stage T3 prostate cancer: a report from the Cryo-On-Line Database (COLD) Registry. BJU Int. 2014 May; 113(5):714-8. PMID: 24112776.
      View in: PubMed
    25. van den Bos W, Muller BG, Ahmed H, Bangma CH, Barret E, Crouzet S, Eggener SE, Gill IS, Joniau S, Kovacs G, Pahernik S, de la Rosette JJ, Rouvière O, Salomon G, Ward J, Scardino PT. Focal therapy in prostate cancer: international multidisciplinary consensus on trial design. Eur Urol. 2014 Jun; 65(6):1078-83. PMID: 24444476.
      View in: PubMed
    26. Ward J, Pisters LL. Considerations for patient selection for focal therapy. Ther Adv Urol. 2013 Dec; 5(6):330-7. PMID: 24294291; PMCID: PMC3825108.
    27. Matin SF, Cormier JN, Ward J, Pisters LL, Wood CG, Dinney CP, Royal RE, Huang X, Pettaway CA. Phase 1 prospective evaluation of the oncological adequacy of robotic assisted video-endoscopic inguinal lymphadenectomy in patients with penile carcinoma. BJU Int. 2013 Jun; 111(7):1068-74. PMID: 23551693; PMCID: PMC3651805.
    28. Gittelman MC, Hertzman B, Bailen J, Williams T, Koziol I, Henderson RJ, Efros M, Bidair M, Ward J. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. J Urol. 2013 Jul; 190(1):64-9. PMID: 23416644.
      View in: PubMed
    29. Leibovici D, Chiong E, Pisters LL, Guo CC, Ward J, Andino L, Prokhorova IN, Troncoso P. Pathological characteristics of prostate cancer recurrence after radiation therapy: implications for focal salvage therapy. J Urol. 2012 Jul; 188(1):98-102. PMID: 22578724.
      View in: PubMed
    30. Ward J, Rewcastle JC, Ukimura O, Gill IS. Focal therapy for the treatment of localized prostate cancer: a potential therapeutic paradigm shift awaiting better imaging. Curr Opin Urol. 2012 Mar; 22(2):104-8. PMID: 22273756.
      View in: PubMed
    31. Pisters PW, Pettaway CA, Liu P, Matin SF, Ward J, Leibovici D. Is transureteroureterostomy performed during multi-organ resection for non-urothelial malignancy safe and effective? J Surg Oncol. 2012 Jul 01; 106(1):62-5. PMID: 22259198.
      View in: PubMed
    32. Shih YC, Ward J, Pettaway CA, Xu Y, Matin SF, Davis JW, Thompson BP, Elting LS. Comparative effectiveness, cost, and utilization of radical prostatectomy among young men within managed care insurance plans. Value Health. 2012 Mar-Apr; 15(2):367-75. PMID: 22433769.
      View in: PubMed
    33. Ward J, Jones JS. Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database (COLD) Registry. BJU Int. 2012 Jun; 109(11):1648-54. PMID: 22035200.
      View in: PubMed
    34. Liu H, Zhang T, Chen R, McConkey DJ, Ward J, Curley SA. Multiple kinase pathways involved in the different de novo sensitivity of pancreatic cancer cell lines to 17-AAG. J Surg Res. 2012 Jul; 176(1):147-53. PMID: 22099584.
      View in: PubMed
    35. Dhar N, Ward J, Cher ML, Jones JS. Primary full-gland prostate cryoablation in older men (> age of 75 years): results from 860 patients tracked with the COLD Registry. BJU Int. 2011 Aug; 108(4):508-12. PMID: 21722288.
      View in: PubMed
    36. Ward J. High-intensity focused ultrasound for therapeutic tissue ablation in surgical oncology. Surg Oncol Clin N Am. 2011 Apr; 20(2):389-407, ix. PMID: 21377590.
      View in: PubMed
    37. Ganzer R, Robertson CN, Ward J, Brown SC, Conti GN, Murat FJ, Pasticier G, Rebillard X, Thuroff S, Wieland WF, Blana A. Correlation of prostate-specific antigen nadir and biochemical failure after high-intensity focused ultrasound of localized prostate cancer based on the Stuttgart failure criteria - analysis from the @-Registry. BJU Int. 2011 Oct; 108(8 Pt 2):E196-201. PMID: 21332907.
      View in: PubMed
    38. Ward J. Prostate cancer: HIFU is effective, but associated morbidity still remains unclear. Nat Rev Urol. 2010 Nov; 7(11):597-8. PMID: 21068758.
      View in: PubMed
    39. Auprich M, Chun FK, Ward J, Pummer K, Babaian R, Augustin H, Luger F, Gutschi S, Budäus L, Fisch M, Huland H, Graefen M, Haese A. Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur Urol. 2011 Jan; 59(1):96-105. PMID: 20980098.
      View in: PubMed
    40. Stafford RJ, Shetty A, Elliott AM, Klumpp SA, McNichols RJ, Gowda A, Hazle JD, Ward J. Magnetic resonance guided, focal laser induced interstitial thermal therapy in a canine prostate model. J Urol. 2010 Oct; 184(4):1514-20. PMID: 20727549; PMCID: PMC3915781.
    41. Ward J. Contemporary outcomes of focal therapy in prostate cancer: what do we know so far... World J Urol. 2010 Oct; 28(5):593-7. PMID: 20680294.
      View in: PubMed
    42. Ward J, Jones JS. Classification system: organ preserving treatment for prostate cancer. Urology. 2010 Jun; 75(6):1258-60. PMID: 20080292.
      View in: PubMed
    43. Davis JW, Kim J, Ward J, Wang X, Nakanishi H, Babaian RJ, Troncoso P. Radical prostatectomy findings in patients predicted to have low-volume/low-grade prostate cancer diagnosed by extended-core biopsies: an analysis of volume and zonal distribution of tumour foci. BJU Int. 2010 May; 105(10):1386-91. PMID: 19888979.
      View in: PubMed
    44. Pisters LL, Leibovici D, Blute M, Zincke H, Sebo TJ, Slezak JM, Izawa J, Ward J, Scott SM, Madsen L, Spiess PE, Leibovich BC. Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy. J Urol. 2009 Aug; 182(2):517-25; discussion 525-7. PMID: 19524984.
      View in: PubMed
    45. Blana A, Brown SC, Chaussy C, Conti GN, Eastham JA, Ganzer R, Murat FJ, Pasticier G, Rebillard X, Rewcastle JC, Robertson CN, Thuroff S, Ward J. High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure. BJU Int. 2009 Oct; 104(8):1058-62. PMID: 19388986.
      View in: PubMed
    46. Ward J. Editorial comment on: Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy. Eur Urol. 2010 Mar; 57(3):444-5. PMID: 19303198.
      View in: PubMed
    47. Ward J, Margulis V. Continous improvement of TNM staging system for bladder cancer. Cancer. 2009 Feb 15; 115(4):704-5. PMID: 19117038.
      View in: PubMed
    48. Ward J, Nakanishi H, Pisters L, Babaian RJ, Troncoso P. Cancer ablation with regional templates applied to prostatectomy specimens from men who were eligible for focal therapy. BJU Int. 2009 Aug; 104(4):490-7. PMID: 19220260.
      View in: PubMed
    49. Chen H, Liakou CI, Kamat A, Pettaway C, Ward J, Tang DN, Sun J, Jungbluth AA, Troncoso P, Logothetis C, Sharma P. Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci U S A. 2009 Feb 24; 106(8):2729-34. PMID: 19202079; PMCID: PMC2650334.
    50. Ward J, Pagliaro LC, Pisters LL. Salvage therapy for radiorecurrent prostate cancer. Curr Probl Cancer. 2008 Nov-Dec; 32(6):242-71. PMID: 19064119.
      View in: PubMed
    51. Moul JW, Ward J. Management of the patient with a rising PSA alone. Hematol Oncol Clin North Am. 2006 Aug; 20(4):897-908. PMID: 16861121.
      View in: PubMed
    52. Ward J. Can PSA velocity serve as a surrogate endpoint in trials of hormone-refractory, metastatic prostate cancer? Nat Clin Pract Urol. 2006 Jun; 3(6):310-1. PMID: 16763642.
      View in: PubMed
    53. Ward J. Comments on "single-strand-specific radiosensitization by bromodeoxyuridine" by Cecchini et Al. Radiat Res. 2005 Sep; 164(3):341-2; author reply 342-3. PMID: 16137210.
      View in: PubMed
    54. Ward J, Moul JW. Treating the biochemical recurrence of prostate cancer after definitive primary therapy. Clin Prostate Cancer. 2005 Jun; 4(1):38-44. PMID: 15992460.
      View in: PubMed
    55. Ward J, Moul JW. Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer. Curr Opin Urol. 2005 May; 15(3):187-95. PMID: 15815196.
      View in: PubMed
    56. Ward J, Moul JW. Biochemical recurrence after definitive prostate cancer therapy. Part I: defining and localizing biochemical recurrence of prostate cancer. Curr Opin Urol. 2005 May; 15(3):181-6. PMID: 15815195.
      View in: PubMed
    57. Ward J, Sebo TJ, Blute ML, Zincke H. Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes. J Urol. 2005 Apr; 173(4):1156-60. PMID: 15758726.
      View in: PubMed
    58. Ward J, Moul JW. Rising prostate-specific antigen after primary prostate cancer therapy. Nat Clin Pract Urol. 2005 Apr; 2(4):174-82. PMID: 16474760.
      View in: PubMed
    59. Ward J, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int. 2005 Apr; 95(6):751-6. PMID: 15794776.
      View in: PubMed
    60. Ward J, Zincke H, Bergstralh EJ, Slezak JM, Blute ML. Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. J Urol. 2004 Dec; 172(6 Pt 1):2244-8. PMID: 15538240.
      View in: PubMed
    61. Ward J, Zincke H, Bergstralh EJ, Slezak JM, Myers RP, Blute ML. The impact of surgical approach (nerve bundle preservation versus wide local excision) on surgical margins and biochemical recurrence following radical prostatectomy. J Urol. 2004 Oct; 172(4 Pt 1):1328-32. PMID: 15371834.
      View in: PubMed
    62. Ly A, Tran NQ, Ward J, Milligan JR. Repair of oxidative guanine damage in plasmid DNA by indoles involves proton transfer between complementary bases. Biochemistry. 2004 Jul 20; 43(28):9098-104. PMID: 15248767.
      View in: PubMed
    63. Ward J, Blute ML. Use and timing of radiotherapy in high-risk prostate cancer. JAMA. 2004 Jun 16; 291(23):2817; author reply 2817-8. PMID: 15199027.
      View in: PubMed
    64. Milligan JR, Tran NQ, Ly A, Ward J. Peptide repair of oxidative DNA damage. Biochemistry. 2004 May 04; 43(17):5102-8. PMID: 15109269.
      View in: PubMed
    65. Young CY, Jatoi A, Ward J, Blute ML. The effects of dietary factors on the androgen receptor and related cellular factors in prostate cancer. Curr Med Chem. 2004 Apr; 11(7):909-23. PMID: 15078173.
      View in: PubMed
    66. Milligan JR, Aguilera JA, Hoang O, Ly A, Tran NQ, Ward J. Repair of guanyl radicals in plasmid DNA by electron transfer is coupled to proton transfer. J Am Chem Soc. 2004 Feb 18; 126(6):1682-7. PMID: 14871098.
      View in: PubMed
    67. Ward J, Bartsch G, Sebo TJ, Pinggera GM, Blute ML, Zincke H. Pathologic characterization of prostate cancers with a very low serum prostate specific antigen (0-2 ng/mL) incidental to cystoprostatectomy: is PSA a useful indicator of clinical significance? Urol Oncol. 2004 Jan-Feb; 22(1):40-7. PMID: 14969803.
      View in: PubMed
    68. Ward J, Blute ML, Slezak J, Bergstralh EJ, Zincke H. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol. 2003 Nov; 170(5):1872-6. PMID: 14532796.
      View in: PubMed
    69. Kminek G, Bada JL, Pogliano K, Ward J. Radiation-dependent limit for the viability of bacterial spores in halite fluid inclusions and on Mars. Radiat Res. 2003 Jun; 159(6):722-9. PMID: 12751954; PMCID: PMC3919141.
    70. Ward J, Zincke H. Radical prostatectomy for the patient with locally advanced prostate cancer. Curr Urol Rep. 2003 Jun; 4(3):196-204. PMID: 12756082.
      View in: PubMed
    71. Ward J, Blute ML. Chemoprevention of prostate cancer. Expert Rev Anticancer Ther. 2003 Apr; 3(2):203-14. PMID: 12722880.
      View in: PubMed
    72. Gray Sears CL, Ward J, Sears ST, Puckett MF, Kane CJ, Amling CL. Prospective comparison of computerized tomography and excretory urography in the initial evaluation of asymptomatic microhematuria. J Urol. 2002 Dec; 168(6):2457-60. PMID: 12441939.
      View in: PubMed
    73. Ward J, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. The influence of pNx/pN0 grouping in a multivariate setting for outcome modeling in patients with clear cell renal cell carcinoma. J Urol. 2002 Jul; 168(1):56-60. PMID: 12050492.
      View in: PubMed
    74. Kane CJ, Tarman GJ, Summerton DJ, Buchmann CE, Ward J, O'Reilly KJ, Ruiz H, Thrasher JB, Zorn B, Smith C, Morey AF. Multi-institutional experience with buccal mucosa onlay urethroplasty for bulbar urethral reconstruction. J Urol. 2002 Mar; 167(3):1314-7. PMID: 11832721.
      View in: PubMed
    75. Ward J. The radiation-induced lesions which trigger the bystander effect. Mutat Res. 2002 Feb 20; 499(2):151-4. PMID: 11827708.
      View in: PubMed
    John's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _